NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 135)
Posted On: 09/20/2023 3:51:10 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh. Genprex is developing technologies to administer disease-fighting genes that will provide new therapies in the fight against cancer and diabetes for large patient populations. In regard to the company’s diabetes approach, the Pdx1 and MafA genes are delivered directly to the pancreas through a novel infusion process (gene therapy candidates ‘GPX-002’ and ‘GPX-003’),” a recent article reads. “We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program,” Genprex chairman, president and CEO Rodney Varner is quoted as saying. “The addition of this license to MafB promoter technology expands and strengthens the potential for this novel gene therapy to treat type 1 and type 2 diabetes.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh. Genprex is developing technologies to administer disease-fighting genes that will provide new therapies in the fight against cancer and diabetes for large patient populations. In regard to the company’s diabetes approach, the Pdx1 and MafA genes are delivered directly to the pancreas through a novel infusion process (gene therapy candidates ‘GPX-002’ and ‘GPX-003’),” a recent article reads. “We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program,” Genprex chairman, president and CEO Rodney Varner is quoted as saying. “The addition of this license to MafB promoter technology expands and strengthens the potential for this novel gene therapy to treat type 1 and type 2 diabetes.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Genprex Inc. (GNPX) Stock Research Links
Scroll down for more posts ▼